“Winning the Golden Ticket has had a major impact on Nosis Bio,” says Chad Miller, principal scientist and a co-founder of the company. “More important than the free lab space, the Golden Ticket opened the door to the Foundation, which has an incredible track record of supporting biotech companies to develop revolutionary therapeutics.”
Read post
“In protein design, until the last couple of years, successes were rare,” said Fraser, a professor of bioengineering and therapeutic sciences in UCSF's School of Pharmacy. “(AI has) just been a sea change. Stuff works now.”
Those successes are elevating a new generation of AI-focused drug-development companies in the Bay Area, including Profluent Bio, a 20-person Berkeley startup founded by the leaders of the Salesforce project. In the wake created by ChatGPT and a wealth of biological data, those companies may be key to AI’s evolving ability to fix human ills.
Read post
“We want to turn off an RNA transcript and prevent it from being expressed by default,” CSO Eerik Kaseniit, a former graduate student who worked on the technology in Gao’s lab, told Endpoints News in an interview.
Radar’s scientists do that by adding a stop codon — three genetic letters that are the molecular equivalent of a red light — in front of the mRNA therapy, which prevents cells from reading the message.
Read post
Radar Therapeutics thinks it can push the technology to the next level – and into more diseases – with safety switches that boost cell specificity, safety, and accessibility. The biotech, co-founded by MIT professor and synthetic biology pioneer Jim Collins, launched Thursday with a $13.4-million seed round led by NfX Bio and boasting Eli Lilly as one of its investors.
Read post
Radar Therapeutics emerged from stealth this week with an announcement that it had raised $13.4 million in an oversubscribed seed financing round led by NfX Bio. Eli Lilly & Co, Biovision, and KdT Ventures also joined the round, with participation from PearVC, BEVC, and other investors. They will use the funds to advance various internal programs, expand their team, and pursue partnership opportunities.
Read post
Coagulant Therapeutics is developing a novel pipeline of therapeutics to treat acute bleeds led by CT-001, a next-generation factor VIIa (FVIIa) molecule.
Read post
Daniel Georgiev, co-founder and chief executive officer of Sampling Human, will be speaking on applications for the technology at the SynBioBeta conference. “At Sampling Human, we recognize the great lengths scientists go to today in order to obtain high-quality single-cell data,” said Daniel Georgiev. “Our plug and play products are designed to deliver reliable solutions with higher specificity, lower cost and ease of use for measuring the growing number of specialized cells in the body."
Read post
Mekonos' silicon nanoneedle-based delivery platform will provide Accelerated Bio with high efficiency, high viability cell engineering – including the precise and gentle delivery of multiplexed genetic cargo into its pluripotent hTSCs.
Read post
AI-powered Profluent Bio released the world's first open-source, AI-generated gene editor, the Berkeley company said Monday, an effort that could help more scientists develop CRISPR medicines to fix a range of diseases.
Profluent, a roughly 20-person company launched by former Salesforce researcher Ali Madani and University of Washington assistant professor Alexander Meeske, said its OpenCRISPR-1 gene editor uses a protein, which it developed with large language models, and guide RNA that shuttles a cutting protein where it needs to go.
Read post
With creativity, collaboration, and determination, staff across these three entities have coordinated with numerous campus units to build a vibrant community of startup companies that are commercializing campus-originated innovations in therapeutics and climate technology.
Read post
A "mentorship mentality" shapes the trajectory of aspiring leaders. By mentoring others, leaders not only hone their technical knowledge but also practice crucial soft skills such as effective communication. Moreover, mentorship fosters a sense of community and support, enabling CEOs to cultivate a strong network.
Read post
Much as ChatGPT learns to generate language by analyzing Wikipedia articles, books and chat logs, Profluent’s technology creates new gene editors after analyzing enormous amounts of biological data, including microscopic mechanisms that scientists already use to edit human DNA.
Read post
Our tenant Minutia, with CEO and co-founder Katy Digovich listed as recipient, won a $1,192,586 DISC0 award for "Immune cloaking of human stem cell-derived insulin producing cells for curative cell therapy without immunosuppression."
Read post
“We hope this new oral therapeutic targeting proinflammatory immunometabolism will have 'pipeline-in-a-pill' potential,” says CEO and co-founder Greg Timblin. “Once it garners FDA approval in one inflammatory indication, it could be used in the clinic as a treatment across multiple inflammatory diseases. Perhaps it could even provide benefit to patients with more complex diseases where excessive inflammation is thought to be a driving factor, such as cardiometabolic and neurodegenerative diseases.”
Read post
The Innovation Award recognizes the real contribution Bakar Labs makes to the regional economy by supporting entrepreneurs building new companies, hiring skilled workers, bringing in investment, expanding their operations, and forging partnerships as they develop cures and solutions for the most urgent challenges that face us in human health. Since the incubator’s launch in November 2021, the 38 companies that we’ve hosted have raised more than $380 million and created more than 300 jobs.
Read post